CMD-602 targets a range of cancers which express the WT1 antigen. Cell Medica acquired this product from the Cell and Gene Therapy Catapult (CGT Catapult). The original research was conducted at University College London (UCL) and Imperial College London. CGT Catapult has progressed the clinical development studying the safety and efficacy of the product in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). With eight patients treated, the product has demonstrated promising results.

Cell Medica plans to continue the current clinical development investigating the WT1-TCR for AML and MDS while also preparing a second-generation product which incorporates the Dominant TCR technology licensed from UCL in 2016. Applying the Dominant TCR technology is expected to achieve greater efficacy in the solid tumor setting and the Phase 1 trial for the second-generation product is targeted for late 2018.